ProKidney Corp. Class A Ordinary Shares PROK
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-04T00:59:47.600Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-03T23:44:41.391930219Z
FundamentalsAlpha Vantage · ready · quarter 2026-06-30 · fetched 2026-11-04T00:59:46.061828+00:00
ProKidney Corp. Class A Ordinary Shares options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 0.91 | 682.8% | 62.4% | |||
| 25Δ | 1.03 | 629.7% | 50.8% | |||
| 30Δ | 1.10 | 579.2% | 45.3% | |||
| 35Δ | 1.17 | 528.8% | 39.8% | |||
| 40Δ | 1.23 | 478.4% | 34.3% | |||
| 45Δ | 1.30 | 428.0% | 28.8% | |||
| 50Δ | 1.36 | 377.6% | 23.3% | |||
| 55Δ | 1.43 | 327.1% | 17.8% | |||
| 60Δ | 1.50 | 276.7% | 12.3% | |||
| 65Δ | 1.12 | 472.6% | 41.1% | 1.95 | 354.1% | 12.0% |
| 70Δ | 1.05 | 511.8% | 39.9% | 2.39 | 378.5% | 10.2% |
| 75Δ | 0.97 | 545.0% | 37.5% | 2.82 | 396.1% | 8.3% |
| 80Δ | 0.81 | 545.0% | 28.3% | 4.60 | 490.3% | 7.4% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 0.91
- IV
- 682.8%
- B/E move
- 62.4%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.03
- IV
- 629.7%
- B/E move
- 50.8%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.10
- IV
- 579.2%
- B/E move
- 45.3%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.17
- IV
- 528.8%
- B/E move
- 39.8%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.23
- IV
- 478.4%
- B/E move
- 34.3%
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.30
- IV
- 428.0%
- B/E move
- 28.8%
50Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.36
- IV
- 377.6%
- B/E move
- 23.3%
55Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.43
- IV
- 327.1%
- B/E move
- 17.8%
60Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.50
- IV
- 276.7%
- B/E move
- 12.3%
65Δ
- Pseudo strike
- 1.12
- IV
- 472.6%
- B/E move
- 41.1%
- Pseudo strike
- 1.95
- IV
- 354.1%
- B/E move
- 12.0%
70Δ
- Pseudo strike
- 1.05
- IV
- 511.8%
- B/E move
- 39.9%
- Pseudo strike
- 2.39
- IV
- 378.5%
- B/E move
- 10.2%
75Δ
- Pseudo strike
- 0.97
- IV
- 545.0%
- B/E move
- 37.5%
- Pseudo strike
- 2.82
- IV
- 396.1%
- B/E move
- 8.3%
80Δ
- Pseudo strike
- 0.81
- IV
- 545.0%
- B/E move
- 28.3%
- Pseudo strike
- 4.60
- IV
- 490.3%
- B/E move
- 7.4%
Options history
Table
| Date | IV (%) |
|---|---|
| 250.59% | |
| 255.98% |
Biotechnology
PRQR
ProQR Therapeutics NV, a biopharmaceutical company, is dedicated to the discovery and development of RNA-based therapies for the treatment of genetic disorders. The company is…
More →PRTA
Prothena Corporation plc, an advanced stage clinical company, is focused on the discovery and development of new therapies for life-threatening diseases in the United States. The…
More →PTCT
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for patients with rare disorders. The company is…
More →PTGX
Description unavailable
More →PVLA
Palvella Therapeutics, Inc. is an innovative biotechnology firm dedicated to developing transformative therapies for rare genetic disorders resulting from specific gene mutations.…
More →PYPD
PolyPid Ltd., an advanced stage biopharmaceutical company, develops, manufactures and markets products based on the Polymer Lipid Encapsulation Matrix (PLEX) platform to address…
More →